Jewelfish study
Web13 sep. 2024 · The primary objectives of this study are to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured by change in Children's Hospital of Philadelphia-Infant Test of Neuromuscular Disorders (CHOP-INTEND) total score (Part B); to examine the safety … Web15 jun. 2024 · Among the five abstracts featured, new data includes 12-month safety, pharmacodynamic and interim exploratory efficacy data from the JEWELFISH study of EVRYSDI in people previously treated with SMA-targeting therapies across a broad range of ages (1–60 years), SMA types (1–3) and SMN2 copy number (1-5).
Jewelfish study
Did you know?
WebM Scoto,12 on behalf of the JEWELFISH Study Group The JEWELFISH population is broad and heterogeneous with a high degree of motor impairment at baseline *Three patients in the nusinersen group had also received olesoxime previously. †One patient in the onasemnogene abeparvovec group received treatment with onasemnogene Web27 jul. 2024 · LPS_BP39054_JEWELFISH_interim results_January2024_English (PDF, 1.0 MB) Final Results. Go back to trial. ... With the exception of studies of olesoxime, AVXS-101, or nusinersen: Previous participation in any investigational drug or device study within 90 days prior to screening, ...
Web13 okt. 2024 · The JEWELFISH study enrolled the broadest and most diverse patient population ever studied in an SMA trial. Of the 174 people enrolled, 36% (n=63) were adults, 63% (n=105) had a Hammersmith Functional Motor Scale Expanded (HFMSE) score of less than 10 at baseline, meaning their disease was very severe, and 83% (n=139) had … Web29 jul. 2024 · This study enrolled the broadest patient population ever studied in an SMA trial. Data from the JEWELFISH study, which included a diverse patient population with a high degree of motor impairment, show that Evrysdi ® has a favorable safety profile in patients previously treated with other SMA targeting therapies.
Web11 jun. 2024 · The study is currently recruiting. JEWELFISH (NCT03032172) is an open-label exploratory trial designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics ... Web14 okt. 2024 · JEWELFISH, an open-label exploratory trial, is unique in that it enrolled the broadest and most diverse patient population ever studied in an SMA trial. Of those …
Web13 apr. 2024 · Design/Methods: JEWELFISH ( NCT03032172) is an ongoing, multicenter, open-label study evaluating the safety, tolerability and PK/PD relationship of daily oral risdiplam in non-naïve patients with SMA (inclusion …
WebJEWELFISH Research type Research Study Full title AN OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND … how to change ink cartridge canon pixma 490Web12 okt. 2024 · Bild: ZVG Der Pharmakonzern Roche sieht die Wirksamkeit seines SMA-Mittels Evrysdi (Risdiplam) über ein breites Patientenspektrum auch nach zwei Jahren bestätigt. Am Mittwoch legte der Konzern entsprechende Daten aus seiner Jewelfish-Studie vor, in der Patienten mit der erblichen Muskelerkrankung Spinale Muskelatrophie … michael jordan card 45Web13 feb. 2024 · The JEWELFISH study (NCT03032172) was designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of risdiplam in … how to change ink cartridge canon pixma 3522Web12 jun. 2024 · Enrollment for the JEWELFISH study, assessing safety and pharmacodynamics of risdiplam in previously treated patients with SMA, who are now receiving risdiplam, is complete (n=174). michael jordan card 543Web13 apr. 2024 · The open-label Phase 2 JEWELFISH study (NCT03032172) enrolled 174 SMA patients, ages 6 months to 60 years, who previously received other SMA-targeting therapies. These include Genentech’s investigational compounds, Biogen’s Spinraza (nusinersen) — the first approved SMA-targeted therapy — and Novartis’ one-time gene … michael jordan card 65Web6 jul. 2024 · Risdiplam update from Roche. 6 July 2024. On 5th July Roche sent us the following information, as per our request to be kept up to date on their current research regarding the RG7916 development programme which will now be known as “risdiplam”. The programme has now reached a number of key milestones. They also announced a … michael jordan card 41Web11 jun. 2024 · Roche has reported new interim data from two studies of Evrysdi (risdiplam); JEWELFISH and RAINBOWFISH. Data from JEWELFISH, an ongoing open-label study primarily evaluating the safety of Evrysdi in people aged 1 to 60 years who have been previously treated with another SMA-targeting therapy, including nusinersen and … michael jordan career free throw percentage